中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2013年
2期
89-92
,共4页
肺腺癌新分类%微乳头%EGFR%KRAS%临床病理学特征
肺腺癌新分類%微乳頭%EGFR%KRAS%臨床病理學特徵
폐선암신분류%미유두%EGFR%KRAS%림상병이학특정
new classification of lung adenocarcinoma%micropapillary pattern%EGFR%KRAS%clinical and pathological features
目的:探讨伴微乳头成分的肺腺癌(pulmonary adenocarcinoma with a micropapillary pattern,MPPAC)EGFR、KRAS基因突变情况及其临床病理学特征.方法:根据2011年的肺腺癌新分类诊断标准,以是否伴有微小乳头状结构(micropapillary pat?tern,MPP),将144例肺腺癌病例分为MPP阳性组77例和MPP阴性组77例.MPP阳性组中又按MPP所占比例分为(+、++、+++)三亚组.RT-PCR法检测两组EGFR、KRAS基因突变情况.结果:在144例肺腺癌病例中EGFR突变62例(43.1%),KRAS突变9例(6.25%),EGFR 突变与性别(P=0.018)和肿瘤体积(P=0.016)有关.MPP 阳性组 EGFR 突变率高于 MPP 阴性组(P<0.001);KRAS突变率低于MPP阴性组(P=0.016).EGFR基因突变频率在MPP三亚组中无明显不同(P=0.932).结论:伴微乳头结构的肺腺癌EGFR突变频率高于肺腺癌其它亚型,KRAS突变频率低于肺腺癌其它亚型,说明其有独特的分子生物学特点.
目的:探討伴微乳頭成分的肺腺癌(pulmonary adenocarcinoma with a micropapillary pattern,MPPAC)EGFR、KRAS基因突變情況及其臨床病理學特徵.方法:根據2011年的肺腺癌新分類診斷標準,以是否伴有微小乳頭狀結構(micropapillary pat?tern,MPP),將144例肺腺癌病例分為MPP暘性組77例和MPP陰性組77例.MPP暘性組中又按MPP所佔比例分為(+、++、+++)三亞組.RT-PCR法檢測兩組EGFR、KRAS基因突變情況.結果:在144例肺腺癌病例中EGFR突變62例(43.1%),KRAS突變9例(6.25%),EGFR 突變與性彆(P=0.018)和腫瘤體積(P=0.016)有關.MPP 暘性組 EGFR 突變率高于 MPP 陰性組(P<0.001);KRAS突變率低于MPP陰性組(P=0.016).EGFR基因突變頻率在MPP三亞組中無明顯不同(P=0.932).結論:伴微乳頭結構的肺腺癌EGFR突變頻率高于肺腺癌其它亞型,KRAS突變頻率低于肺腺癌其它亞型,說明其有獨特的分子生物學特點.
목적:탐토반미유두성분적폐선암(pulmonary adenocarcinoma with a micropapillary pattern,MPPAC)EGFR、KRAS기인돌변정황급기림상병이학특정.방법:근거2011년적폐선암신분류진단표준,이시부반유미소유두상결구(micropapillary pat?tern,MPP),장144례폐선암병례분위MPP양성조77례화MPP음성조77례.MPP양성조중우안MPP소점비례분위(+、++、+++)삼아조.RT-PCR법검측량조EGFR、KRAS기인돌변정황.결과:재144례폐선암병례중EGFR돌변62례(43.1%),KRAS돌변9례(6.25%),EGFR 돌변여성별(P=0.018)화종류체적(P=0.016)유관.MPP 양성조 EGFR 돌변솔고우 MPP 음성조(P<0.001);KRAS돌변솔저우MPP음성조(P=0.016).EGFR기인돌변빈솔재MPP삼아조중무명현불동(P=0.932).결론:반미유두결구적폐선암EGFR돌변빈솔고우폐선암기타아형,KRAS돌변빈솔저우폐선암기타아형,설명기유독특적분자생물학특점.
Objective: To assess the correlation of pulmonary micropapillary adenocarcinoma with epidermal growth factor receptor (EGFR) and KRAS mutation status and determine their clinicopathological features. Methods: We divided 144 cases of lung adenocarcinoma into two groups according to the new diagnostic criteria for the classification of lung adenocarcinoma (published in 2011): the micropapillary pattern (MPP)-positive group and the MPP-negative group, each with 77 cases. The MPP-positive group was further subdivided into three subgroups (+, ++, and +++) according to the proportion of the micropapillary component. EGFR and KRAS gene mutations were detected by real time PCR polymerase chain reaction. Results: Of the 144 cases of lung adenocarcinoma, 62 cases (43.1%) have EGFR gene mutation, whereas 9 cases (6.25%) have KRAS gene mutation. EGFR mutation is shown to be associated with gender (P=0.018) and tumor volume (P=0.016). EGFR mutation is significantly higher in the MPP-positive group than in the MPP-negative group (P<0.001), whereas KRAS mutation is lower in MPP-positive group than in MPP-negative group (P=0.016). No significant difference in the frequency of EGFR mutation among the three MPP-positive subgroups was indicated (P=0.932). Conclusion: The frequency of EGFR mutation in MPPAC is higher compared with that in the other subtypes of lung adenocarcinoma. The frequency of KRAS mutation in MPPAC is lower compared with that in the other subtypes of lung adenocarcinoma. These results indicate its unique molecular biological characteristic.
